Leerink reiterates Ovid Therapeutics stock rating on safety data

Leerink reiterated an Outperform and $5 price target on Ovid (NASDAQ:OVID), implying a 74% upside from the current $2.31 share price and valuing the company at about $300M; shares have gained ~381% over the past year. The firm flagged encouraging safety at the higher OV329 dose and the absence of ophthalmic findings, and Ovid plans a placebo-controlled Phase 2 in focal onset seizures in Q2 2026. Ovid reported Q4 2025 EPS of $0.06 vs consensus -$0.1137 (surprise +152.8%) and revenue $718,000 vs $80,670 expected (surprise +790.1%), representing a material earnings and revenue beat likely to drive stock-level re-rating.

Analysis

The recent safety data removes a key binary overhang and should structurally compress OVID’s idiosyncratic risk premium — but that compression is only meaningful if the datapoints scale with exposure and duration. A small, clean safety signal tends to unlock two second-order pathways: greater licensing/partnership interest from mid/large pharmas wary of class risk, and a faster regulatory dialogue that can shorten timelines by months, not years.

Competitively, the biggest beneficiaries are not only OVID but any small-cap programs targeting GAT inhibition; a molecule-specific safety narrative re-opens the pool of acquirers and co-development partners who had previously written off the mechanism. Conversely, programs with ambiguous ocular datasets or larger patient exposures will look comparatively unattractive and may face financing stress, creating consolidation opportunities.

Key risks are classic binary biotech: late-emergent ocular findings in larger cohorts, trial design or enrollment delays, and financing/dilution if the company needs to scale a registrational program without a partner. Timing matters — the commercial and regulatory upside plays out over 12–24 months while safety reversals can vaporize value in weeks.

From a market microstructure perspective, implied volatility is likely elevated; that creates opportunity for directional exposure via longer-dated, structured option positions rather than outright unhedged stock exposure. Liquidity is uneven in small caps, so execution and position sizing should assume wide intraday moves and limited ability to exit quickly.

Key Decisions for Investors

• Directional long: Buy OVID equity sized 1–2% of portfolio as a high-risk, high-reward speculative holding (time horizon 12–24 months). Hedge with a protective put (3–6 month expiry) sized to limit downside to ~40% of position value. Rationale: idiosyncratic upside from successful dose-escalation and partnership interest vs defined downside protection.
• Options LEAP spread: Buy long-dated OVID calls (12–18 month LEAP) and sell nearer-term calls (3–6 months) to fund part of the premium. This calendar/ratio structure captures long-term upside while monetizing near-term theta and reduces vega exposure vs naked calls.
• Pair/sector hedge: Long OVID / short XBI (SPDR Biotech ETF) sized to neutralize broad biotech beta (time horizon 6–18 months). Purpose is to isolate idiosyncratic clinical/regulatory upside and protect against sector-wide selloffs that commonly swamp small-cap winners.
• Event-risk caution: If planning to trade into upcoming trial milestones, avoid >3% portfolio allocation into a single binary; set automatic profit-taking at +50–100% and hard stop at -40% to preserve capital for redeployment. If implied volatility remains >historical realized, prefer spreads to reduce premium paid.